Corrected: AbbVie, AndroGel partner owe $448 million in antitrust case - U.S. judge

(Corrects damages award to say $448 million, not $488 million)

A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.

The ruling by U.S. District Judge Harvey Bartle in Philadelphia came in an antitrust lawsuit filed in 2014 by the Federal Trade Commission against AbbVie and its partner Besins Healthcare Inc.

TRENDING NOW

Sebi plans to introduce 'fast track' concept for public issuance of debt securities

China's consumer prices fall fastest in 3 years, factory-gate deflation deepens

Investors to focus on inflation data from India, US: Data

NT Awards 2023: Zee Business shines in five categories

Finance Ministry to empanel merchant bankers, law firms for disinvestment via OFS, dribbling

Animal Box Office Collection: Ranbir Kapoor-starrer touches Rs 600 crore mark worldwide | Check OTT release details

FPIs invest Rs 26,505 crore in equities in 1st six sessions of December

COVID-19 Update: India records 148 new coronavirus cases, infection tally stands at 4.50 crore

NPS (National Pension System): How to create a corpus of Rs 5 crore with Rs 442 investment/day? After retirement, you will get Rs 2.5 lakh every month

Delhi Weather Update: National Capital records minimum temperature at 8.5°C

CLAT 2023 result to be released today on consortiumofnlus.ac.in - Final answer key out

Tata Group submits application to set up semiconductor processing plant in Assam: CM Sarma

Need to follow consistent EV policy, no need for company-specific sops: FICCI EV Committee Chair

Government approves 100% packaging of food grains in jute bags

Manu Ahuja, CEO of Jubilant Agri and Consumer Products, passes away

The decision followed a non-jury trial that tested the ability of the U.S. regulator to fight efforts by major pharmaceutical companies to prevent the sale of cheaper generic versions of their drugs.

The FTC had accused Chicago-based AbbVie and Besins of filing baseless patent infringement lawsuits against competitors to delay the launch of their generic products.

The FTC, which had sought $1.35 billion, said the order was the largest monetary award ever in an antitrust case that it litigated in court. Bartle said liability would be apportioned between AbbVie and Besins according their agreed royalty rates.

"It sends a clear signal that pharmaceutical companies can’t use baseless litigation to forestall competition from low-cost generics," FTC Chairman Joe Simons said in a statement.

Representatives for AbbVie did not respond to requests for comment. A lawyer for Besins had no immediate comment.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)